Peter Kufer
- Oncology top 0.2%
- CAR-T cell therapy research 63
-
- Monoclonal and Polyclonal Antibodies Research 81
- Immunology top 0.5%
- Immunotherapy and Immune Responses 29
- Immune Cell Function and Interaction 16
- T-cell and B-cell Immunology 13
- Hematology top 1%
-
- Lymphoma Diagnosis and Treatment 10
-
- Glycosylation and Glycoproteins Research 16
-
- Chronic Lymphocytic Leukemia Research 11
- Co-authors
- Patrick A. BaeuerleRalf C. BargouGert RiethmüllerG. RiethmüllerRalf LutterbüseBernd SchlerethRobert HofmeisterGerhard Zugmaier
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Peter Kufer
111 papers receiving 7.1k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Oncology 5.1k
- Radiology, Nuclear Medicine and Imaging 3.6k
- Immunology 3.0k
- Hematology 748
- Pathology and Forensic Medicine 782
Countries citing papers authored by Peter Kufer
This map shows the geographic impact of Peter Kufer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kufer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kufer more than expected).
Fields of papers citing papers by Peter Kufer
This network shows the impact of papers produced by Peter Kufer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kufer. The network helps show where Peter Kufer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Kufer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 58 | |
| 2 | 2019 | 51 | |
| 3 | 2016 | 17 | |
| 4 | 2014 | 106 | |
| 5 | 2012 | 101 | |
| 6 | 2010 | 162 | |
| 7 | 2009 | 144 | |
| 8 | Abstract #3252: Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110 | 2009 | 14 |
| 9 | 2009 | 43 | |
| 10 | Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models | 2008 | 2 |
| 11 | 2008 | 58 | |
| 12 | 2007 | 66 | |
| 13 | Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3 | 2007 | 3 |
| 14 | 2005 | 8 | |
| 15 | 2005 | 77 | |
| 16 | 2004 | 54 | |
| 17 | 2003 | 155 | |
| 18 | 2000 | 16 | |
| 19 | 1997 | 37 | |
| 20 | 1996 | 18 |
About Peter Kufer
Peter Kufer is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, Genetics and Virology, having authored 113 papers that have together received 7.5k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (81 papers), CAR-T cell therapy research (63 papers), Immunotherapy and Immune Responses (29 papers), Glycosylation and Glycoproteins Research (16 papers), Immune Cell Function and Interaction (16 papers), T-cell and B-cell Immunology (13 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Oncology (5.1k citations), Radiology, Nuclear Medicine and Imaging (3.6k citations), Immunology (3.0k citations), Hematology (748 citations) and Pathology and Forensic Medicine (782 citations). Peter Kufer has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Patrick A. Baeuerle, Ralf C. Bargou, Gert Riethmüller, G. Riethmüller, Ralf Lutterbüse, Bernd Schlereth, Robert Hofmeister, Gerhard Zugmaier, Christian Brandl and Matthias Mack. Their work appears in journals such as Cancer Research, Blood, Cancer Immunology Immunotherapy, Journal of Clinical Oncology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.